Clinical Trial Update: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing standard chemotherapy to therapy with CPX-351 and/or gilteritinib for newly diagnosed acute myeloid leukemia with or without FL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)
• Xospata (gilteritinib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: RECRUITING